← Leaderboards
Eva Garland
Agile Sciences, Inc.
$3,867,273
Attributed
$3,867,273
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.7M · FY2010–18$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$3,867,273 · 4
By mechanism
N01$2,745,321 · 1
R43$821,952 · 2
R41$300,000 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Small Molecule”
- David Heimbrook · Leidos Biomedical Research, Inc.$251,072,489
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Peter C Adamson · National Childhood Cancer Foundation$143,645,434
- Mark S Klempner · Tufts Medical Center$128,021,180
- Stuart L Schreiber · Harvard University (Medical School)$79,067,419
- Edward A Dennis · University Of California, San Diego$73,030,813
Research focus
Small MoleculeGram-Negative BacteriaIn VitroSeriesIn VivoLeadPre-ClinicalToxic EffectCommunicable DiseasesStaphylococcus AureusBacteriaPharmaceutical ChemistryBacterial ResistanceStructureAntimicrobial ResistancePseudomonas AeruginosaReportingGram-Positive BacteriaMethicillin Resistant Staphylococcus Aureus (Organism)Infectious Disease TreatmentDrug CandidateFutureMicrobial BiofilmsScience
Grant awards (8)
Optimizing Lead Therapeutic Compounds Against Infectious Diseases$499,839
N01 · FY2018 · AI · contact PI
Optimizing Lead Therapeutic Compounds Against Infectious Diseases$282,822
N01 · FY2017 · AI · contact PI
Optimizing Lead Therapeutic Compounds Against Infectious Diseases$272,974
N01 · FY2016 · AI · contact PI
Optimizing Lead Therapeutic Compounds Against Infectious Diseases$1,689,686
N01 · FY2015 · AI · contact PI
Development of Novel Anti-Biofilm Compounds for Treating Chronic Wounds$300,000
R41 · FY2011 · AI · contact PI
Prevention of Bacterial Biofilms on CSF Shunts through the Incorporation of Novel$284,496
R43 · FY2011 · NS · contact PI
Prevention of Bacterial Biofilms on CSF Shunts through the Incorporation of Novel$285,619
R43 · FY2010 · NS · contact PI
Targeting Oral Biofilms with 2-Aminoimidazole/Triazole Conjugates$251,837
R43 · FY2010 · DE · contact PI